Alteogen lands $365m licensing deal

Korean biotechnology firm Alteogen said Wednesday it has signed an exclusive licensing agreement worth up to $365 million with a global pharmaceutical company. Under the deal, the latter will develop and commercialize subcutaneous formulations of biologic drugs using Alteogen's proprietary recombinant human hyaluronidase platform ALT-B4. Also known by its generic name berahyaluronidase alfa, ALT-B4 is Alteogen's proprietary recombinant human hyaluronidase developed using the company's Hybrozyme